• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • Skip to investors navigation
Scholar Rock

Scholar Rock

Discovery and Development of Innovative Medicines

  • Careers
  • Newsroom
  • Contact Us
  • Patients & Families
    • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access

    Learn about our commitment to creating possibilities for those living with serious disease.

    Patients & Families

  • Our Company
    • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors

    Meet Scholar Rock, a biopharmaceutical company committed to improving lives.

    Our Company

  • Our Science
    • Our Science
    • Platform
    • Publications & Posters

    Discover how our breakthrough approach treats complex disease at its biological root.

    Our Science

  • Our Pipeline
    • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
      • Cardiometabolic Disorders
    • Immuno-Oncology
      • Cancer (solid tumors)
    • Fibrotic Diseases
      • Fibrosis
    • Hematology
      • Anemia
  • Investors & Media
    • Investor Overview
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filinigs
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
HomePatients & FamiliesExpanded Access

Expanded Access

Scholar Rock is committed to creating new possibilities for people living with serious disease. As we advance multiple investigational therapies through clinical development, our goal is to provide timely and appropriate access to therapies with life-changing potential.

Patients generally obtain access to investigational therapies prior to regulatory approval by participating in clinical trials. We are purposeful in designing inclusive clinical trials that are consistent with regulatory guidance for the inclusion of eligible patients.

However, there may be instances where a patient with a serious or life-threatening disease or condition is not eligible to participate in a clinical trial and has exhausted all treatment options. In these cases, health authorities may grant permission for Scholar Rock to provide a treating physician with an investigational therapy pre-approval outside of a clinical trial. The pre-approval access is called expanded access, or compassionate use.

Scholar Rock has an active Expanded Access Program (EAP) in the US for our investigational product, apitegromab (NCT06877689) for the treatment of eligible patients with SMA. More information about this program can be found here.

Expanded access treatment can only be provided under limited circumstances, meaning that Scholar Rock will not be able to fulfill all requests. Requests for expanded access to investigational therapies must be made by a qualified physician on the patient’s behalf. In compliance with health authority regulations, patients themselves cannot make a request for treatment and are advised to discuss with the treating physician.

For additional Information about Scholar Rock’s clinical trials and EAPs, including Expanded Access Treatment Protocols and Scholar Rock’s investigational medicines, please contact our Medical Information team at [email protected] or 1-855-MED-SRRK. 

Contact Us

Contact Us for More Information About Expanded Access

Clinical Trials

Learn More About Our Clinical Trials

Footer

Scholar Rock, Inc.
301 Binney Street, 3rd Floor
Cambridge, MA 02142

Phone: 857.259.3860
[email protected]

LinkedIn X, formally Twitter
© 2025 All Rights Reserved
  • Community Guidelines
  • Expanded Access
  • Privacy Policy
  • Terms of Use

We are Scholar Rock.

A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients.

Learn More About Our Pipeline

  • Community Guidelines
  • Expanded Access
  • Privacy Policy
  • Terms of Use
logo
  • Patients & Families
    • Areas of Focus
      • Spinal Muscular Atrophy
    • Patient Stories
    • Clinical Trials
    • Resources
    • Expanded Access
  • Our Company
    • Mission & Vision
    • Newsroom
    • Careers
    • Management Team
    • Board of Directors
    • Partnering
  • Our Science
    • Platform
    • Publications & Posters
  • Our Pipeline
    • Neuromuscular and Obesity
      • Spinal Muscular Atrophy
      • Cardiometabolic Disorders
    • Immuno-Oncology
      • Cancer (solid tumors)
    • Fibrotic Diseases
      • Fibrosis
    • Hematology
      • Anemia
  • Investors & Media
    • Press Releases
      • Archived Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historical Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Investor FAQs
    • Contact IR or Media
  • Careers
  • Newsroom
  • Contact Us

You are now leaving the Scholar Rock website.

This external link is provided for your convenience. Scholar Rock is not responsible for content on external websites.

Continue